GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the ...

The company said the results will be submitted for peer-reviewed scientific publication and will be used to support regulatory submissions to the FDA ... and older. AREXVY is approved for the ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

The trial's findings, which are set to be submitted to peer-reviewed scientific publications and regulatory bodies like the FDA and EMA ... term nerve pain. AREXVY, approved in over 50 countries ...

The trial's findings, which are set to be submitted to peer-reviewed scientific publications and regulatory bodies like the FDA and EMA ... rashes and potentially long-term nerve pain. AREXVY, ...

You can schedule an appointment at your local pharmacy, such as CVS, Walgreens, Safeway, or your primary care physician to get the RSV vaccine. The CDC said it is safe to get your RSV, flu and COVID ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

The FDA has approved GSK’s Arexvy shot for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older, shortly after it was recommended for approval ...